All In Biotech

Drug Trial Radar · NCT06006104

Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer

A Phase I/II Clinical Study to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-4357 in Patients With PSMA Positive Advanced Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

49

Planned (sponsor's estimate)

Start

Sep 30, 2023

Primary completion

Sep 30, 2024

Study completion Oct 31, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.

Conditions

  • Advanced Prostate Cancer

Interventions

  • HRS-4357 injectionDrug

    HRS-4357 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prog Dose limiting toxicity (DLT)Time frame: up to 9 months follow-up
  2. recommended phase 2 dose (RP2D)Time frame: up to 9 months follow-up
  3. recommended dosing cycle.Time frame: up to 9 months follow-up
  4. PSA50 response rateTime frame: up to 12 weeks follow-up

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.